Lipase Inhibition and Hormonal Status, Body Composition and Gastrointestinal Processing of a Liquid High‐Fat Mixed Meal in Moderately Obese Subjects
- 1 November 1995
- journal article
- clinical trial
- Published by Wiley in Obesity Research
- Vol. 3 (6), 573-581
- https://doi.org/10.1002/j.1550-8528.1995.tb00192.x
Abstract
DRENT, MADELEINE L, CORRIE POPP‐SNIJDERS, HERMAN J ADER, JAN BMJ JANSEN AND EDUARD A VAN DER VEEN. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high‐fat mixed meal in moderately obese subjects. Obes Res. The effect of Orlistat, a lipase inhibitor used in the treatment of obesity was studied on gastrointestinal transit time, on body composition and on hormones known to be influenced by the degree of hydrolysis of nutritional triglycerides or by reduced nutrient intake and absorption. After a placebo run‐in period 14 patients were randomized to a 12‐week treatment period on Orlistat 360 mg per day (mean body weight 93.1 ± 9.8 kg) or placebo (mean body weight 90.7 ± 10.5 kg). At randomization and after 12 weeks body weight, body composition, thyroid hormones, catecholamines, insulin‐like growth factor I (IGF‐I) and IGF‐binding protein 3 were measured. During 4 hours after consumption of a liquid fat‐rich mixed meal containing study medication, 15 g lactulose and 25 g xylose, blood levels of glucose, insulin, c‐peptide, glucagon, triglycerides, free fatty acids, cholecys‐tokinin, pancreatic polypeptide and xylose and expiration air levels of hydrogen were measured. Weight loss was 4.2 ± 3.5 kg in the Orlistat group versus 3.0 ± 1.9 kg in the placebo group. Fat mass decreased to an equal degree, whereas lean body mass remained stable. No differences were found for thyroid hormones, catecholamines, IGF‐I and IGFBP‐3 levels. By comparing the areas under the curve (AUC) and the peak levels at randomization (acute effects) of insulin and c‐peptide a tendency was found to be increased in the Orlistat group, whereas those of xylose were increased significantly, suggesting faster gastric empyting after Orlistat. No differences were found in the other parameters. By comparing the changes in responses (longer term effects) no significant differences were found. In conclusion, the presence in the gut of undigested and unabsorbed fat does not seem to have a relevant influence on hormonal status and body composition in a small group of moderately obese patients.Keywords
This publication has 49 references indexed in Scilit:
- Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysisJournal of Clinical Endocrinology & Metabolism, 1992
- Effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone on serum IGF-binding proteins in calorically restricted adultsJournal of Clinical Endocrinology & Metabolism, 1992
- Evaluation of Metabolic Effects of Substitution of Complex Carbohydrates for Saturated Fat in Individuals with Obesity and NIDDMDiabetes Care, 1991
- Plasma Cholecystokinin Concentrations in Patients With Advanced Chronic PancreatitisPancreas, 1986
- Plasma cholecystokinin concentrations in patients with pancreatic insufficiency measured by sequence-specific radioimmunoassaysDigestive Diseases and Sciences, 1984
- Assessment of the reproducibility of the lactulose H2 breath test as a measure of mouth to caecum transit time.Gut, 1983
- One-hour blood-xylose in cystic fibrosis.Archives of Disease in Childhood, 1978
- ONE-HOUR BLOOD-XYLOSE SCREENING-TEST FOR CŒLIAC DISEASE IN INFANTS AND YOUNG CHILDRENThe Lancet, 1973